2025-03-25
How can complementary GLP-1 nutritional products be developed to leverage synergistic effects and mitigate adverse side effects?
S-equol for Menopause: A Natural Estrogen Alternative to Relieve Hot Flashes & Boost Bone Health
2025-03-22
S-equol, an emerging ingredient, is gaining attention in the women’s health supplement market, particularly for menopause management.
Natural Products Expo West 2025: Insights into Future Industry Trends
2025-03-07
From March 5 to 7, 2025, the global natural products industry turned its attention to Anaheim, USA, for the Natural Products Expo West. Bonerge also actively participated, highlighting core products such as Fisetin, Urolithin A, Dihydroberberine, AKK, and S-equol, joining the global community in discussing future trends in the health and nutrition sector.
Urolithin A: Activating AMPK & SIRT1 to Reverse Aging Clocks | Science-Backed Benefits
2025-03-03
Urolithin A enhances circadian rhythm amplitude in aging cells by modulating the SIRT1-PER2 axis and chromatin remodeling, offering potential benefits for circadian health.
Bonerge announce the new 108 Person Clinical Trial: Exploring Skin and Organ Anti-Aging Innovations
2025-02-01
Bonerge announced the initiation of its clinical trial, focusing on Fisetin, Urolithin A, and Ergothioneine. Involving 108 participants, this trial aims to evaluate their combined effects on skin health and organ rejuvenation when taking orally, providing more reliable options for the market.
BeFisetin® is gaining the First Fisetin Ingredient SA-GRAS Certification
2025-01-03
In 2024, Bonerge's premium fisetin branded ingredient, BeFisetin®, initiated the SA-GRAS (Self-Affirmed Generally Recognized As Safe) certification process, with completion expected in February 2025. This certification underscores Bonerge's unwavering commitment to product safety, quality control and serves as a key milestone in its expansion into the global fisetin market.
Our Products
IPV4 / IPV6